Terms: = Prostate cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
28 results:
1. The PTEN Conundrum: How to Target PTEN-Deficient prostate cancer.
Turnham DJ; Bullock N; Dass MS; Staffurth JN; Pearson HB
Cells; 2020 Oct; 9(11):. PubMed ID: 33105713
[TBL] [Abstract] [Full Text] [Related]
2. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant prostate cancer.
Guan X; Sun D; Lu E; Urrutia JA; Reiter RE; Rettig M; Evans CP; Lara P; Gleave M; Beer TM; Thomas GV; Huang J; Aggarwal RR; Quigley DA; Foye A; Chen WS; Youngren J; Weinstein AS; Stuart JM; Feng FY; Small EJ; Xia Z; Alumkal JJ
Clin Cancer Res; 2020 Sep; 26(17):4616-4624. PubMed ID: 32727885
[TBL] [Abstract] [Full Text] [Related]
3. B7-H4 is a potential prognostic biomarker of prostate cancer.
Li H; Piao L; Liu S; Cui Y; Xuan Y
Exp Mol Pathol; 2020 Jun; 114():104406. PubMed ID: 32088189
[TBL] [Abstract] [Full Text] [Related]
4. clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.
Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Roobol MJ; Helleman J; van Leenders GJLH
Histopathology; 2020 Apr; 76(5):755-762. PubMed ID: 31944367
[TBL] [Abstract] [Full Text] [Related]
5. Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival.
Giordano F; Naimo GD; Nigro A; Romeo F; Paolì A; De Amicis F; Vivacqua A; Morelli C; Mauro L; Panno ML
Drug Des Devel Ther; 2019; 13():4265-4274. PubMed ID: 31908413
[TBL] [Abstract] [Full Text] [Related]
6. Role of miRNA-Regulated cancer Stem Cells in the Pathogenesis of Human Malignancies.
Khan AQ; Ahmed EI; Elareer NR; Junejo K; Steinhoff M; Uddin S
Cells; 2019 Aug; 8(8):. PubMed ID: 31530793
[TBL] [Abstract] [Full Text] [Related]
7. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer.
Ding Y; Li N; Dong B; Guo W; Wei H; Chen Q; Yuan H; Han Y; Chang H; Kan S; Wang X; Pan Q; Wu P; Peng C; Qiu T; Li Q; Gao D; Xue W; Qin J
J Clin Invest; 2019 Feb; 129(2):759-773. PubMed ID: 30496141
[TBL] [Abstract] [Full Text] [Related]
8. Targeting Galectin-1 Impairs Castration-Resistant prostate cancer Progression and Invasion.
Shih TC; Liu R; Wu CT; Li X; Xiao W; Deng X; Kiss S; Wang T; Chen XJ; Carney R; Kung HJ; Duan Y; Ghosh PM; Lam KS
Clin Cancer Res; 2018 Sep; 24(17):4319-4331. PubMed ID: 29666302
[No Abstract] [Full Text] [Related]
9. The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.
Morell C; Bort A; Vara D; Ramos-Torres A; Rodríguez-Henche N; Díaz-Laviada I
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):248-57. PubMed ID: 27324222
[TBL] [Abstract] [Full Text] [Related]
10. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant prostate cancer Pretreated With Docetaxel Chemotherapy: A prostate cancer clinical Trial Consortium Study.
Vaishampayan U; Shevrin D; Stein M; Heilbrun L; Land S; Stark K; Li J; Dickow B; Heath E; Smith D; Fontana J
Urology; 2015 Dec; 86(6):1206-11. PubMed ID: 26375845
[TBL] [Abstract] [Full Text] [Related]
11. Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.
Liu J; You P; Chen G; Fu X; Zeng X; Wang C; Huang Y; An L; Wan X; Navone N; Wu CL; McKeehan WL; Zhang Z; Zhong W; Wang F
Oncogene; 2016 Apr; 35(14):1750-9. PubMed ID: 26096936
[TBL] [Abstract] [Full Text] [Related]
12. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression.
Li S; Ma Y; Xie C; Wu Z; Kang Z; Fang Z; Su B; Guan M
Oncotarget; 2015 Sep; 6(26):22587-97. PubMed ID: 26041887
[TBL] [Abstract] [Full Text] [Related]
13. Methylation status of insulin-like growth factor-binding protein 7 concurs with the malignance of oral tongue cancer.
Chen LH; Liu DW; Chang JL; Chen PR; Hsu LP; Lin HY; Chou YF; Lee CF; Yang MC; Wen YH; Hsu WL; Weng CF
J Exp Clin Cancer Res; 2015 Feb; 34(1):20. PubMed ID: 25880247
[TBL] [Abstract] [Full Text] [Related]
14. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
Ferraldeschi R; Nava Rodrigues D; Riisnaes R; Miranda S; Figueiredo I; Rescigno P; Ravi P; Pezaro C; Omlin A; Lorente D; Zafeiriou Z; Mateo J; Altavilla A; Sideris S; Bianchini D; Grist E; Thway K; Perez Lopez R; Tunariu N; Parker C; Dearnaley D; Reid A; Attard G; de Bono J
Eur Urol; 2015 Apr; 67(4):795-802. PubMed ID: 25454616
[TBL] [Abstract] [Full Text] [Related]
15. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer.
Wang T; Liu Z; Guo S; Wu L; Li M; Yang J; Chen R; Xu H; Cai S; Chen H; Li W; Wang L; Hu Z; Zhuang Q; Xu S; Wang L; Liu J; Ye Z; Ji JY; Wang C; Chen K
Oncotarget; 2014 Jun; 5(11):3611-21. PubMed ID: 25003983
[TBL] [Abstract] [Full Text] [Related]
16. Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer.
Du Z; Fei T; Verhaak RG; Su Z; Zhang Y; Brown M; Chen Y; Liu XS
Nat Struct Mol Biol; 2013 Jul; 20(7):908-13. PubMed ID: 23728290
[TBL] [Abstract] [Full Text] [Related]
17. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.
Choucair K; Ejdelman J; Brimo F; Aprikian A; Chevalier S; Lapointe J
BMC Cancer; 2012 Nov; 12():543. PubMed ID: 23171135
[TBL] [Abstract] [Full Text] [Related]
18. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer.
Shirotake S; Miyajima A; Kosaka T; Tanaka N; Kikuchi E; Mikami S; Okada Y; Oya M
Am J Pathol; 2012 Mar; 180(3):1008-1016. PubMed ID: 22226738
[TBL] [Abstract] [Full Text] [Related]
19. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.
Meng X; Brachova P; Yang S; Xiong Z; Zhang Y; Thiel KW; Leslie KK
PLoS One; 2011; 6(6):e20920. PubMed ID: 21687633
[TBL] [Abstract] [Full Text] [Related]
20. E17K substitution in akt1 in prostate cancer.
Boormans JL; Korsten H; Ziel-van der Made AC; van Leenders GJ; Verhagen PC; Trapman J
Br J Cancer; 2010 May; 102(10):1491-4. PubMed ID: 20407443
[TBL] [Abstract] [Full Text] [Related]
[Next]
